The Global Cerebral Malaria Therapeutics Market size is expected to reach USD 5.4 billion by 2028 from USD 4.6 billion in 2018, growing at a CAGR of 3.8%. The factors such as increasing public awareness about malaria and rising prevalence rates are driving the growth of this market. In addition, increased number of new product launches are fueling the growth prospects of this market globally.
Malaria is a tropical disease caused by the parasite Plasmodium, which can be transmitted through mosquito bites. Symptoms of malaria depend on whether it's been contracted for the first time or if there have already been several infections before and include fever, chills, body aches, headache with vomiting, and diarrhea. Malaria affects more than 200 million people each year causing about 450 000 deaths annually mostly among children in Africa under age five. Malaria prevention methods like the use of bed nets to prevent mosquitoes from biting are available that also provide protection against other diseases such as Zika Virus Disease (ZVD), Dengue Fever (DF), and yellow fever.
On the basis of Type, the market is segmented as Quinine, Artemisinin Derivatives.
Quinine is a naturally occurring substance found in the bark of the cinchona tree. It has been used for centuries to treat malaria, and today it remains an important part of malaria treatment regimens around the world. Quinine works by blocking or inhibiting certain proteins that are needed by malarial parasites within red blood cells to survive.
Artemisinin Derivatives are a class of drugs derived from the plant Artemisia annua, or sweet wormwood. These compounds have been shown to be highly effective against malaria parasites that harbor resistance to other treatments. Their efficacy is due in part to their ability to inhibit the parasite's production of proteins needed for survival and reproduction inside red blood cells as well as blocking enzymes required for DNA synthesis within malarial parasites.
On the basis of Application, the market is segmented into Retail Pharmacies, Online Pharmacies, Hospital Pharmacies, and Drug Stores. In the retail pharmacy segment, cerebral malaria therapeutics are used for the treatment of cerebral malaria. In this region, quinine has been prescribed by physicians and pharmacists in a high proportion because it’s cheaper than artemisinin derivatives such as Artemether-lumefantrine (Coartem) or Artemisinin-based Combination Therapy (ACT). The use of drugs relies on several factors including availability at lower prices; accessibility to patients; prescriptions from physicians or their relatives. Quinine was also preferred due to its low incidence rates of serious adverse events compared with other available therapies such as ACT.
On the basis of Region, the market is segmented into North America, Latin America, Europe, Asia Pacific, and Middle East & Africa. The cerebral malaria therapeutics market in the Americas is driven by a higher incidence of neurological diseases such as epilepsy or Alzheimer’s disease (AD). North America accounts for the highest market share in the global cerebral malaria therapeutics market followed by Europe trailed by the Asia Pacific. In terms of growth rate, Latin America has shown considerable potential that can be attributed to increasing awareness about health hazards related to this disease among people living there. The Middle East & Africa region occupies a small share owing to high prevalence rates and lack of economic resources required for treatment. The report also covers the current competitive scenario involving key players like Sanofi SE., Bayer AG., Novartis International AG., GlaxoSmithKline plc.
The growth factors for the global cerebral malaria therapeutics market are as follows:
- Development of new drugs by various research and development institutions, such as Johnson & Johnson.
- Demand in developing countries due to increase in population, particularly Asia Pacific region.
- High incidence rates of cerebral malaria among HIV/AIDS patients with low CDR response rate.
Up Market Research published a new report titled “Cerebral Malaria Therapeutics Market research report which is segmented by Types (Quinine, Artemisinin Derivatives), By Applications (Retail Pharmacies, Online Pharmacies, Hospital Pharmacies, Drug Store), By Players/Companies Novartis, Cipla, Zydus Cadila, Ipca Laboratories, Sanofi, Eisai”.
|Report Attributes||Report Details|
|Report Title||Cerebral Malaria Therapeutics Market Research Report|
|By Type||Quinine, Artemisinin Derivatives|
|By Application||Retail Pharmacies, Online Pharmacies, Hospital Pharmacies, Drug Store|
|By Companies||Novartis, Cipla, Zydus Cadila, Ipca Laboratories, Sanofi, Eisai|
|Regions Covered||North America, Europe, APAC, Latin America, MEA|
|Historical Year||2018 to 2019 (Data from 2010 can be provided as per availability)|
|Number of Pages||205|
|Number of Tables & Figures||144|
|Customization Available||Yes, the report can be customized as per your need.|
The report covers comprehensive data on emerging trends, market drivers, growth opportunities, and restraints that can change the market dynamics of the industry. It provides an in-depth analysis of the market segments which include products, applications, and competitor analysis.
The market is segmented by Type Quinine, Artemisinin Derivatives and By Application Retail Pharmacies, Online Pharmacies, Hospital Pharmacies, Drug Store.
Some of the companies that are profiled in this report are:
Cerebral Malaria Therapeutics Market research report delivers a close watch on leading competitors with strategic analysis, micro and macro market trend and scenarios, pricing analysis and a holistic overview of the market situations in the forecast period. It is a professional and a detailed report focusing on primary and secondary drivers, market share, leading segments and geographical analysis. Further, key players, major collaborations, merger & acquisitions along with trending innovation and business policies are reviewed in the report.
Key Benefits for Industry Participants & Stakeholders:
Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa (MEA). North America region is further bifurcated into countries such as U.S., and Canada. The Europe region is further categorized into U.K., France, Germany, Italy, Spain, Russia, and Rest of Europe. Asia Pacific is further segmented into China, Japan, South Korea, India, Australia, South East Asia, and Rest of Asia Pacific. Latin America region is further segmented into Brazil, Mexico, and Rest of Latin America, and the MEA region is further divided into GCC, Turkey, South Africa, and Rest of MEA.
We have studied the Cerebral Malaria Therapeutics Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2028.
How you may use our products:
Reasons to Purchase the Cerebral Malaria Therapeutics Market Report:
Some other reports from this category!